Abstract: The present invention provides a preventative/therapeutic agent for cancer capable of selectively and effectively killing cancer cells. A medicament of the present invention prepared by combining at least one selected from a substance that inhibits the activity of an enzyme belonging to the acyl-CoA synthase family and a substance that inhibits expression of a gene for an enzyme belonging to the acyl-CoA synthase family, with at least one selected from a substance that inhibits the activity of fatty acid synthase and a substance that inhibits expression of a fatty acid synthase gene and the like can be used as a preventative/therapeutic agent for cancer capable of selectively and effectively killing cancer cells.

Abstract: A compound or its salt that inhibits the activity of a protein having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1; a compound or its salt that inhibits the expression of a gene for the protein; an antisense polynucleotide comprising a nucleotide sequence complementary or substantially complementary to the nucleotide sequence of a polynucleotide encoding the protein or a partial peptide thereof or a part of the nucleotide sequence; an antibody against the protein; etc. are useful as preventive/therapeutic agents for cancer, apoptosis promoters for cancer cells, or the like.

Abstract: The present inventors intended to search for substances that can regulate the expression of a molecular chaperone, GRP78, using the expression of GRP78 as an indicator. As a result, a novel tetronic acid derivative, versipelostatin compound (also known as JL68) shown in formula (I) having the activity of suppressing GRP78 expression was isolated from the metabolite of Streptomyces versipellis strain 4083-SVS6.

Abstract: The invention relates to a set of isolated marker genes comprising at least one gene identified as having differential expression as between patients who are responders and non responders to an erbB receptor tyrosine kinase inhibitor; said gene set comprising one or more genes selected from at least the group consisting of the 51 genes listed herein including gene-specific oligonucleotides derived from said genes; and uses of such sets in diagnostic applications.

Abstract: A method of judging whether a patient is sensitive to imatinib or not, in case where the patient is suffering from a disease such as CML to be treated by administration of imatinib, that is, a method for judging whether the administration of imatinib is effective for the therapy of the disease or not, is disclosed.

Abstract: The present invention relates to an anthranilic acid derivative expressed by the following formula (1) or the following formula (2), or its pharmacologically permissible salt or solvate.

Abstract: A cancer remedy comprising a compound represented by the following formula as an active ingredient: wherein, X represents a group represented by either of the following formulae: wherein, R1 and R2 represent each a hydrogen atom, a hydroxy group, a trihalomethyl group, a C1-C12 alkoxy group or alkylthio group, a (substituted) C7-C11 aralkyloxy group or a (substituted) C3-C10 alkenyloxy group; R4 and R5 represent each a hydrogen atom, a halogen atom, a C1-C4 alkyl group or a C1-C4 alkoxy group; A represents —O—, —S—, —S(?O)—, —S(?O)2—, —CH2—, —OCH2—, —SCH2, —C(?O)— or —CH(OR6)—; Y represents a hydrogen atom, a halogen atom, a nitro group, a nitrile group, an amino group, —COOR7, —NHCOR8 or —NHSO2R9?; E represents —C(?O)—, —CR10R11C(?O)—, —CH2CH2C(?O)— or —CH?CHC(?O)—; G represents a hydrogen atom, a hydroxy group, —SO2NH2, —COOR3, —CN or a tetrazol-5-yl group; and Z represents a hydrogen atom, a halogen atom, a nitro group or a methyl group.

Abstract: The present inventors intended to search for substances that can regulate the expression of a molecular chaperone, GRP78, using the expression of GRP78 as an indicator. As a result, a novel tetronic acid derivative, versipelostatin compound (also known as JL68) shown in formula (I) having the activity of suppressing GRP78 expression was isolated from the metabolite of Streptomyces versipellis strain 4083-SVS6. Versipelostatin can be obtained from the culture supernatant by culturing the above-mentioned Streptomyces versipellis strain 4083-SVS6.

Abstract: The present invention relates to an anthranilic acid derivative expressed by the following formula (1) or the following formula (2), or its pharmacologically permissible salt or solvate.

Abstract: A cancer remedy comprising a compound represented by the following formula as an active ingredient: 1

Abstract: The present invention relates to an anthranilic acid derivative expressed by the following formula (1) or the following formula (2), or its pharmacologically permissible salt or solvate.

Abstract: Catechins, known to be components of tea, can inhibit the enzyme activity of telomerase, an enzyme that synthesizes the telomeric DNA which is responsible for stabilizing the chromosome during cell growth. This telomerase inhibiting activity showed the usefulness of catechins as a cancer prevention agent, an anticancer agent, or a cancer retardation agent, or the like.

Abstract: Heterocyclic compounds useful as anticancer drug potentiaters having a potentiating effect on the incorporation of anticancer drugs into cancer cells are disclosed, the compounds each synthesized by, for example, reacting a epoxy compound obtained by reacting a heterocyclic compound with an epihalogenohydrin, with an amine derivative.

Abstract: Agents against drug-resistant tumor cells comprising a 1,4-dihydropyridine derivative represented by the following formula (I): ##STR1## wherein R.sup.1 is an aryl group which may be substituted;R.sup.2 and R.sup.3, which may be the same or different, each is a member selected from the group consisting of an alkyl group, an alkyloxycarbonyl group, an aryloxycarbonyl group, an aralkyloxycarbonyl group, an aminocarbonyl group, a hydroxycarbonyl group, a formyl group, and a cyano group, each of which may be substituted;R.sup.4 and R.sup.5 is a hydrogen atom or a member selected from the group consisting of a lower alkyl group, a hydroxymethyl group, a cyano group, an amino group, a formyl group, and a halogen atom; andR.sup.

Abstract: Novel heterocyclic compounds, which are represented by the following general formula, useful as anticancer drug potentiaters having a potentiating effect on the incorporation of anticancer drugs into cancer cells, the compounds each synthesized by, for example, reacting a epoxy compound obtained by reacting a heterocyclic compound with an epihalogenohydrin, with an amine derivative.

Abstract: Novel heterocyclic compounds, which are represented by the following general formula, useful as anticancer drug potentiaters having a potentiating effect on the incorporation of anticancer drugs into cancer cells, the compounds each synthesized by, for example, reacting a epoxy compound obtained by reacting a heterocyclic compound with an epihalogenohydrin, with an amine derivative.

Abstract: Monoclonal antibodies are disclosed that may be produced by hybridomas obtained by fusing a mouse spleen cell immunized with an ADRIAMYCIN.RTM.-resistant human tumor cell and a mouse myeloma cell and which inhibit selectively the growth of cancer cells possessing pleiotropic drug resistance or enhance their sensitivity to said drug.

Abstract: 5-((3,4-dimethoxyphenetyl)methylamino)- 2-(3,4-dimethoxy-phenyl)-2-isopropylvaleronitrile or a pharmaceutically acceptable salt thereof is effective to prevent metastasis of cancer.

Abstract: An agent for enhancing antitumor activity of antitumor agents comprising as the active ingredient diltiazem or a pharmaceutically acceptable acid addition salt thereof, an antitumor composition comprising the diltiazem or an acid addition salt thereof and a conventional antitumor agent, and further a method for treating tumors by administering diltiazem or an acid addition salt thereof together with a conventional antitumor agent in oral or parenteral route to patients suffering from various tumors. Said active diltiazem or a salt thereof is effective for enhancing the antitumor activity of antitumor agents because it can enhance sensitivity of tumor cells to antitumor agents regardless the tumor cells have resistance to the antitumor agents or not.